Inventory: A selection of Lancet studies dated October 31, 2020

1. The effect of assisted radiotherapy on event-free survival in prostate cancer patients immediately after root-based surgery DOI: https://doi.org/10.1016/S0140-6736 (20)31952-8 Recently, researchers conducted a randomized controlled study to compare the effects of ancillary radiotherapy or early remedial radiotherapy on local or late prostate cancer patients after a root-based prostateectomy.
in adult patients with medium to high risk, limited or localized advanced prostate cancer participated in the study, assisted radiotherapy or early remedial radiotherapy immediately after a cure-all prostatectomy, and tested for progression events in patients, including biochemic progression (prostate-specific antigens. PSA≥0.4ng/mL, rising after completion of any postoperative radiotherapy), clinical or radiological progression, other treatment, death from prostate cancer, or randomization of PSA levels above 2.0ng/ml.
end of the study was event-free survival.
3 queues, a total of 2,153 patients completed the study, with an average follow-up time of 60 months to 78 months and a maximum follow-up time of 132 months.
1,075 patients received assisted radiotherapy and 1,078 patients received early remedial radiotherapy.
baselines were similar, with an average age of 64-65 years, and the majority of patients (1671 cases (77.6 per cent)) had a Gleason score of 7.
all trials were assessed as having a lower risk of bias.
study found that assisted radiotherapy showed no significant improvement in event-free survival (HR 0.95) compared to early-stage resuscitation radiotherapy, and that five-year event-free survival rate (89% vs. 88%) increased by only 1 percentage point, with overall results consistent between trials.
: The impact of prostate cancer treatment strategies on the PSA process DOI: https://doi.org/10.1016/S0140-6736 (20)31553-1 The best time for postoperative radiotherapy for prostate cancer is uncertain.
researchers recently compared the effects of complementary radiotherapy and rescuing radiotherapy on the biogenic process of prostate-specific antigens (PSA) in patients.
RADICALS-RT study, patients with at least one biochemical progression risk factor (pathological stage 3 or 4, Gleason scored 7-10, positive edge, or preoperative PSA ≥10 ng/mL) after a root-and-treated prostatectomy were recruited.
patients were randomly treated with assisted radiotherapy or saved radiotherapy strategies (PSA≥0.1 ng/mL or three consecutive elevateds based on PSA biopic progress.
observational indicators were no far-end metastasis, and results were reported on bio-chemical progression-free survival rates, hormone-free therapy, safety and patient reporting.
1,396 patients participated in the study, 699 (50%) received resuscitation radiotherapy and 697 (50%) received assisted radiotherapy.
of patients with the disease was 65 years, and the medium follow-up time was 4.9 years.
649 (93%) of the 697 participants in the
auxiliary radiotherapy group received treatment within six months, and 228 (33%) of the 699 participants in the rescue radiotherapy group received radiotherapy within eight years of the random group.
85 per cent and 88 per cent (HR: 1.10) were 85 per cent and 88 per cent, respectively, in the secondary assisted radiotherapy group and in the rescue radiotherapy group.
93% of the assisted radiotherapy group did not require unused hormone therapy after 5 years, compared with 92% of the rescue radiotherapy group (HR:0.88).
self-described urinary incontinence was more severe when patients in the auxiliary radiotherapy group were 1 year old (average score 4.8 vs. 4.0).
6 percent of individuals in the assisted radiotherapy group reported 3-4 levels of urethra stenosis within 2 years, while 4 percent in the rescue radiotherapy group.
3: SYNTAX II 2020 scores a personalized selection for blood transport reconstruction in patients with complex coronary artery disease based on DOI:https://doi.org/10.1016/S0140-6736(20)32114-0The usual randomized controlled trial is a gold standard for testing the efficacy of new treatments, usually with average therapeutic outcomes as the primary endpoint and conclusion.
, in clinical practice, it is often unscientific to develop treatment strategies for patients based on the overall average efficacy due to individual differences.
recently tried to develop a personalized decision-making tool for personalized selection of the best blood transport reconstruction strategy for patients with complex coronary artery disease.
SYNTAXES study as a multi-center, randomized controlled trial.
patients with coronary veins with three lesions and left stem lesions were recruited and randomly treated with persetretic coronary artery interventional therapy (PCI) or coronary artery bypass transplantation (CABG). The
team used Cox regression models to develop clinical prognossis indicators that predict death within 10 years, and in the second phase combined them with a designated treatment (PCI or CABG) and two pre-specified efficacy regulators (determined based on disease type and anatomy SYNTAX score). The
team developed a predictive model to predict the risk of major adverse cardiovascular events (defined as compound outcomes of total death, non-fatal stroke, or non-fatal myocardial infarction) in patients receiving PCI or CABG over a five-year basis, and then cross-validated them to assess the predictive effects of the model.
cross-validation, the newly developed SYNTAX Score II model (SYNTAX II 2020) showed good 10-year all-cause death (PCI group C index 0.73, CABG group C index 0.73) and 5 year major adverse cardiovascular events (0.65 and 0.71) prediction in both treatment groups.
in external validation, the SYNTAX II 2020 score showed effective judgment and was a good predictive predicter of major adverse cardiovascular events over five years (PCI group C index 0.67, CABG group C index 0.62).
in the trial population, the prediction showed that CABG benefited more from PCI treatment, and the actual clinical results confirmed this prediction.
MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that state "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here